Skip to content

Clinical trials

Influenza, Human trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Influenza, Human Country / region: China Clear all

134 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20051
20063
20073
20083
200915
20103
20116
20126
20134
20143
20153
20164
20172
20186
20198
20206
202111
20225
20239
202413
202510
20268

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed88
Unknown status19
Recruiting8
Not yet recruiting8
Active, not recruiting6
Terminated2
Enrolling by invitation2
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Sinovac Biotech Co., Ltd15
Jiangsu Province Centers for Disease Control and Prevention12
Capital Medical University8
Shanghai Institute Of Biological Products8
Jiangxi Qingfeng Pharmaceutical Co. Ltd.7
The University of Hong Kong7
Ab&B Bio-tech Co., Ltd.JS6
Nanjing Zenshine Pharmaceuticals5
China National Biotec Group Company Limited4
Hualan Biological Engineering, Inc.4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Influenza, Human134
Respiratory Tract Infections8
COVID-196
Orthomyxoviridae Infections6
Virus Diseases6
Common Cold3
Influenza in Birds3
Pneumonia, Pneumococcal3
Respiratory Tract Diseases3
Heart Failure2

Trials

Showing 51 to 75 of 134. Each trial links to its page on Pharma Observatory.

34 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.